Role of B cells in common variable immune deficiency

Expert Review of Clinical Immunology

Volumn 5, Issue 5, 2009, Pages 557-564

  Ahn, Sam ^a   Cunningham Rundles, Charlotte ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Antibody; B cell; CVID; Memory B cell; Primary immune deficiency

Indexed keywords

ANTIBODY; CD19 ANTIGEN; CD27 ANTIGEN; IMMUNOGLOBULIN; TOLL LIKE RECEPTOR; TRANSMEMBRANE ACTIVATOR AND CAML INTERACTOR;

B LYMPHOCYTE; COMMON VARIABLE IMMUNODEFICIENCY; CYTOPENIA; GENETIC DISORDER; GRANULOMATOSIS; HUMAN; LYMPHADENOPATHY; MEMORY CELL; REVIEW; SIGNAL TRANSDUCTION; SPLENOMEGALY;

EID: 77949813614     PISSN: 1744666X     EISSN: None     Source Type: Journal    
DOI: 10.1586/eci.09.43     Document Type: Review

References (80)

1. Hammarstrom L, Vorechovsky I, Webster D. Selective IgA deficiency (SIgAD) and common variable immunodeficiency (CVID). Clin. Exp. Immunol. 120(2), 225-231 (2000).
2. Conley ME, Notarangelo LD, Etzioni A. Diagnostic criteria for primary immunodeficiencies. Representing PAGID (Pan-American Group for Immunodeficiency) and ESID (European Society for Immunodeficiencies). Clin. Immunol. 93(3), 190-197 (1999).
3. Chapel H, Lucas M, Lee M et al. Common variable immunodeficiency disorders: division into distinct clinical phenotypes. Blood 112(2), 277-286 (2008).
4. Cunningham-Rundles C, Bodian C. Common variable immunodeficiency: clinical and immunological features of 248 patients. Clin. Immunol. 92(1), 34-48 (1999).
5. LeBien TW, Tedder TF. B lymphocytes: how they develop and function. Blood 112(5), 1570-1579 (2008).
6. McHeyzer-Williams LJ, McHeyzer- Williams MG. Antigen-specific memory B cell development. Annu. Rev. Immunol. 23, 487-513 (2005).
7. MacLennan IC. Germinal centers. Annu. Rev. Immunol. 12, 117-139 (1994).
8. Denz A, Eibel H, Illges H, Kienzle G, Schlesier M, Peter HH. Impaired upregulation of CD86 in B cells of type A common variable immunodeficiency patients. Eur. J. Immunol. 30(4), 1069-1077 (2000).
9. Groth C, Drager R, Warnatz K et al. Impaired up-regulation of CD70 and CD86 in naive (CD27-) B cells from patients with common variable immunodeficiency (CVID). Clin. Exp. Immunol. 129(1), 133-139 (2002).
10. Saxon A, Keld B, Diaz-Sanchez D, Guo BC, Sidell N. B cells from a distinct subset of patients with common variable immunodeficiency (CVID) have increased CD95 (Apo-1/Fas), diminished CD38 expression, and undergo enhanced apoptosis. Clin. Exp. Immunol. 102(1), 17-25 (1995).
11. Schwartz R, Porat YB, Handzel Z et al. Identification of a subset of common variable immunodeficiency patients with impaired B-cell protein tyrosine phosphorylation. Clin. Diagn. Lab. Immunol. 6(6), 856-860 (1999).
12. Taubenheim N, von Hornung M, Durandy A et al. Defined blocks in terminal plasma cell differentiation of common variable immunodeficiency patients. J. Immunol. 175(8), 5498-5503 (2005).
13. Waldmann TA. Disorders of immunoglobulin metabolism. N. Engl. J. Med. 281(21), 1170-1177 (1969).
14. Saiki O, Ralph P. Induction of human immunoglobulin secretion. I. Synergistic effect of B cell mitogen Cowan I plus T cell mitogens or factors. J. Immunol. 127(3), 1044-1047 (1981).
15. Nonoyama S, Farrington M, Ishida H, Howard M, Ochs HD. Activated B cells from patients with common variable immunodeficiency proliferate and synthesize immunoglobulin. J. Clin. Invest. 92(3), 1282-1287 (1993).
16. Bryant A, Calver NC, Toubi E, Webster AD, Farrant J. Classification of patients with common variable immunodeficiency by B cell secretion of IgM and IgG in response to anti-IgM and interleukin-2. Clin. Immunol. Immunopathol. 56(2), 239-248 (1990).
17. Andersen P, Permin H, Andersen V et al. Deficiency of somatic hypermutation of the antibody light chain is associated with increased frequency of severe respiratory tract infection in common variable immunodeficiency. Blood 105(2), 511-517 (2005).
18. Bonhomme D, Hammarstrom L, Webster D et al. Impaired antibody affinity maturation process characterizes a subset of patients with common variable immunodeficiency. J. Immunol. 165(8), 4725-4730 (2000).
19. Levy Y, Gupta N, Le Deist F et al. Defect in IgV gene somatic hypermutation in common variable immuno-deficiency syndrome. Proc. Natl Acad. Sci. USA 95(22), 13135-13140 (1998).
20. Schejbel L, Marquart H, Andersen V et al. Deficiency of somatic hypermutation of immunoglobulin G transcripts is a better predictor of severe respiratory tract infections than lack of memory B cells in common variable immunodeficiency. J. Clin. Immunol. 25(4), 392-403 (2005).
21. Klein U, Rajewsky K, Kuppers R. Human immunoglobulin (Ig)M+IgD+ peripheral blood B cells expressing the CD27 cell surface antigen carry somatically mutated variable region genes: CD27 as a general marker for somatically mutated (memory) B cells. J. Exp. Med. 188(9), 1679-1689 (1998).
22. Maruyama M, Lam KP, Rajewsky K. Memory B-cell persistence is independent of persisting immunizing antigen. Nature 407(6804), 636-642 (2000).
23. Agematsu K, Hokibara S, Nagumo H, Komiyama A. CD27: a memory B-cell marker. Immunol. Today 21(5), 204-206 (2000).
24. Muramatsu M, Kinoshita K, Fagarasan S, Yamada S, Shinkai Y, Honjo T. Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell 102(5), 553-563 (2000).
25. Brouet JC, Chedeville A, Fermand JP, Royer B. Study of the B cell memory compartment in common variable immunodeficiency. Eur. J. Immunol. 30(9), 2516-2520 (2000).
26. Agematsu K, Hokibara S, Nagumo H, Shinozaki K, Yamada S, Komiyama A. Plasma cell generation from B-lymphocytes via CD27/CD70 interaction. Leuk. Lymphoma 35(3-4), 219-225 (1999).
27. Warnatz K, Denz A, Drager R et al. Severe deficiency of switched memory B cells (CD27+IgM-IgD-) in subgroups of patients with common variable immunodeficiency: a new approach to classify a heterogeneous disease. Blood 99(5), 1544-1551 (2002).
28. Warnatz K, Wehr C, Drager R et al. Expansion of CD19hiCD21lo/neg B cells in common variable immunodeficiency (CVID) patients with autoimmune cytopenia. Immunobiology 206(5), 502-513 (2002).
29. Moratto D, Gulino AV, Fontana S et al. Combined decrease of defined B and T cell subsets in a group of common variable immunodeficiency patients. Clin. Immunol. 121(2), 203-214 (2006).
30. Berglund LJ, Wong SW, Fulcher DA. B-cell maturation defects in common variable immunodeficiency and association with clinical features. Pathology 40(3), 288-294 (2008).
31. Piqueras B, Lavenu-Bombled C, Galicier L et al. Common variable immunodeficiency patient classification based on impaired B cell memory differentiation correlates with clinical aspects. J. Clin. Immunol. 23(5), 385-400 (2003).
32. Wehr C, Kivioja T, Schmitt C et al. The EUROclass trial: defining subgroups in common variable immunodeficiency. Blood 111(1), 77-85 (2008).
33. Sanchez-Ramon S, Radigan L, Yu JE, Bard S, Cunningham-Rundles C. Memory B cells in common variable immunodeficiency: clinical associations and sex differences. Clin. Immunol. 128(3), 314-321 (2008).
34. Vlkova M, Thon V, Sarfyova M et al. Age dependency and mutual relations in T and B lymphocyte abnormalities in common variable immunodeficiency patients. Clin. Exp. Immunol. 143(2), 373-379 (2006).
35. Ko J, Radigan L, Cunningham-Rundles C. Immune competence and switched memory B cells in common variable immunodeficiency. Clin. Immunol. 116(1), 37-41 (2005).
36. Detkova D, de Gracia J, Lopes-da-Silva S et al. Common variable immunodeficiency: association between memory B cells and lung diseases. Chest 131(6), 1883-1889 (2007).
37. Jacquot S, Macon-Lemaitre L, Paris E et al. B cell co-receptors regulating T celldependent antibody production in common variable immunodeficiency: CD27 pathway defects identify subsets of severely immuno-compromised patients. Int. Immunol. 13(7), 871-876 (2001).
38. Llobet MP, Soler-Palacin P, Detkova D, Hernandez M, Caragol I, Espanol T. Common variable immunodeficiency: 20-yr experience at a single centre. Pediatr. Allergy Immunol. 20(2), 113-118 (2009).
39. Vodjgani M, Aghamohammadi A, Samadi M et al. Analysis of class-switched memory B cells in patients with common variable immunodeficiency and its clinical implications. J. Investig. Allergol. Clin. Immunol. 17(5), 321-328 (2007).
40. Carsetti R, Rosado MM, Donnanno S et al. The loss of IgM memory B cells correlates with clinical disease in common variable immunodeficiency. J. Allergy Clin. Immunol. 115(2), 412-417 (2005).
41. Cunningham-Rundles C, Cooper DL, Duffy TP, Strauchen J. Lymphomas of mucosal-associated lymphoid tissue in common variable immunodeficiency. Am. J. Hematol. 69(3), 171-178 (2002).
42. Branda RF, Moore AL, Hong R, McCormack JJ, Zon G, Cunningham- Rundles C. B-cell proliferation and differentiation in common variable immunodeficiency patients produced by an antisense oligomer to the rev gene of HIV-1. Clin. Immunol. Immunopathol. 79(2), 115-121 (1996).
43. Gantner F, Hermann P, Nakashima K, Matsukawa S, Sakai K, Bacon KB. CD40-dependent and -independent activation of human tonsil B cells by CpG oligodeoxynucleotides. Eur. J. Immunol. 33(6), 1576-1585 (2003).
44. Hartmann G, Battiany J, Poeck H et al. Rational design of new CpG oligonucleotides that combine B cell activation with high IFN-αinduction in plasmacytoid dendritic cells. Eur. J. Immunol. 33(6), 1633-1641 (2003).
45. He B, Qiao X, Cerutti A. CpG DNA induces IgG class switch DNA recombination by activating human B cells through an innate pathway that requires TLR9 and cooperates with IL-10. J. Immunol. 173(7), 4479-4491 (2004).
46. Krieg AM, Matson S, Fisher E. Oligodeoxynucleotide modifications determine the magnitude of B cell stimulation by CpG motifs. Antisense Nucleic Acid Drug Dev. 6(2), 133-139 (1996).
47. Krieg AM, Yi AK, Matson S et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374(6522), 546-549 (1995).
48. Poeck H, Wagner M, Battiany J et al. Plasmacytoid dendritic cells, antigen, and CpG-C license human B cells for plasma cell differentiation and immunoglobulin production in the absence of T-cell help. Blood 103(8), 3058-3064 (2004).
49. Ruprecht CR, Lanzavecchia A. Toll-like receptor stimulation as a third signal required for activation of human naive B cells. Eur. J. Immunol. 36(4), 810-816 (2006).
50. Bekeredjian-Ding IB, Wagner M, Hornung V et al. Plasmacytoid dendritic cells control TLR7 sensitivity of naive B cells via type I IFN. J. Immunol. 174(7), 4043-4050 (2005).
51. Bernasconi NL, Onai N, Lanzavecchia A. A role for Toll-like receptors in acquired immunity: up-regulation of TLR9 by BCR triggering in naive B cells and constitutive expression in memory B cells. Blood 101(11), 4500-4504 (2003).
52. Glaum MC, Narula S, Song D et al. Toll-like receptor 7-induced naive human B-cell differentiation and immunoglobulin production. J. Allergy Clin. Immunol. 123(1), 224-230 e4 (2009).
53. Cunningham-Rundles C, Radigan L, Knight AK, Zhang L, Bauer L, Nakazawa A. TLR9 activation is defective in common variable immune deficiency. J. Immunol. 176(3), 1978-1987 (2006).
54. Grimbacher B, Hutloff A, Schlesier M et al. Homozygous loss of ICOS is associated with adult-onset common variable immunodeficiency. Nat. Immunol. 4(3), 261-268 (2003).
55. Salzer U, Maul-Pavicic A, Cunningham- Rundles C et al. ICOS deficiency in patients with common variable immunodeficiency. Clin. Immunol. 113(3), 234-240 (2004).
56. Grimbacher B, Warnatz K, Peter HH. The immunological synapse for B-cell memory: the role of the ICOS and its ligand for the longevity of humoral immunity. Curr. Opin. Allergy Clin. Immunol. 3(6), 409-419 (2003).
57. Kanegane H, Agematsu K, Futatani T et al. Novel mutations in a Japanese patient with CD19 deficiency. Genes Immun. 8(8), 663-670 (2007).
58. Van Zelm MC, Reisli I, Van Der M Burg et al. An antibody-deficiency syndrome due to mutations in the CD19 gene. N. Engl. J. Med. 354(18), 1901-1912 (2006).
59. Schaffer AA, Salzer U, Hammarstrom L, Grimbacher B. Deconstructing common variable immunodeficiency by genetic analysis. Curr. Opin. Genet. 17(3), 201-212 (2007).
60. Castigli E, Wilson SA, Garibyan L et al. TACI is mutant in common variable immunodeficiency and IgA deficiency. Nat. Genet. 37(8), 829-834 (2005).
61. Pan-Hammarstrom Q, Salzer U, Du L et al. Re-examining the role of TACI coding variants in common variable immunodeficiency and selective IgA deficiency. Nat. Genet. 39(4), 429-430 (2007).
62. Salzer U, Chapel HM, Webster AD et al. Mutations in TNFRSF13B encoding TACI are associated with common variable immunodeficiency in humans. Nat. Genet. 37(8), 820-828 (2005).
63. Hymowitz SG, Patel DR, Wallweber HJ et al. Structures of APRIL-receptor complexes: like BCMA, TACI employs only a single cysteine-rich domain for high affinity ligand binding. J. Biol. Chem. 280(8), 7218-7227 (2005).
64. Wallweber HJ, Compaan DM, Starovasnik MA, Hymowitz SG. The crystal structure of a proliferation-inducing ligand, APRIL. J. Mol. Biol. 343(2), 283-290 (2004).
65. Garibyan L, Lobito AA, Siegel RM, Call ME, Wucherpfennig KW, Geha RS. Dominant-negative effect of the heterozygous C104R TACI mutation in common variable immunodeficiency (CVID). J. Clin. Invest. 117(6), 1550-1557 (2007).
66. Castigli E, Wilson SA, Scott S et al. TACI and BAFF-R mediate isotype switching in B cells. J. Exp. Med. 201(1), 35-39 (2005).
67. Castigli E, Wilson SA, Elkhal A, Ozcan E, Garibyan L, Geha RS. Transmembrane activator and calcium modulator and cyclophilin ligand interactor enhances CD40-driven plasma cell differentiation. J. Allergy Clin. Immunol. 120(4), 885-891 (2007).
68. Hsu BL, Harless SM, Lindsley RC, Hilbert DM, Cancro MP. Cutting edge: BLyS enables survival of transitional and mature B cells through distinct mediators. J. Immunol. 168(12), 5993-5996 (2002).
69. Litinskiy MB, Nardelli B, Hilbert DM et al. DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL. Nat. Immunol. 3(9), 822-829 (2002).
70. Stein JV, Lopez-Fraga M, Elustondo FA et al. APRIL modulates B and T cell immunity. J. Clin. Invest. 109(12), 1587-1598 (2002).
71. Salzer U, Bacchelli C, Buckridge S et al. Relevance of biallelic versus monoallelic TNFRSF13B mutations in distinguishing disease-causing from risk-increasing TNFRSF13B variants in antibody deficiency syndromes. Blood 113(9), 1967-1976 (2009).
72. Zhang L, Radigan L, Salzer U et al. Transmembrane activator and calciummodulating cyclophilin ligand interactor mutations in common variable immunodeficiency: clinical and immunologic outcomes in heterozygotes. J. Allergy Clin. Immunol. 120(5), 1178-1185 (2007).
73. Seshasayee D, Valdez P, Yan M, Dixit VM, Tumas D, Grewal IS. Loss of TACI causes fatal lymphoproliferation and autoimmunity, establishing TACI as an inhibitory BLyS receptor. Immunity 18(2), 279-288 (2003).
74. Von Bulow GU, Van Deursen JM, Bram RJ. Regulation of the T-independent humoral response by TACI. Immunity 14(5), 573-582 (2001).
75. Yan M, Wang H, Chan B et al. Activation and accumulation of B cells in TACIdeficient mice. Nat. Immunol. 2(7), 638-643 (2001).
76. Thompson JS, Bixler SA, Qian F et al. BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF. Science 293(5537), 2108-2111 (2001).
77. Bacchelli C, Buckridge S, Thrasher AJ, Gaspar HB. Translational mini-review series on immunodeficiency: molecular defects in common variable immunodeficiency. Clin. Exp. Immunol. 149(3), 401-409 (2007).
78. Lavie F, Miceli-Richard C, Ittah M, Sellam J, Gottenberg JE, Mariette X. Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production. Ann. Rheum. Dis. 66(5), 700-703 (2007).
79. Vallerskog T, Heimburger M, Gunnarsson I et al. Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Res. Ther. 8(6), R167 (2006).
80. Knight AK, Radigan L, Marron T, Langs A, Zhang L, Cunningham-Rundles C. High serum levels of BAFF, APRIL, and TACI in common variable immunodeficiency. Clin. Immunol. 124(2), 182-189 (2007).